Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $66.94 USD
Change Today -1.15 / -1.69%
Volume 77.1K
As of 12:42 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

integra lifesciences holding (IART) Snapshot

Open
$67.99
Previous Close
$68.09
Day High
$68.65
Day Low
$66.84
52 Week High
05/20/15 - $69.03
52 Week Low
05/22/14 - $44.07
Market Cap
2.2B
Average Volume 10 Days
191.8K
EPS TTM
$2.30
Shares Outstanding
32.9M
EX-Date
--
P/E TM
29.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for INTEGRA LIFESCIENCES HOLDING (IART)

Related News

No related news articles were found.

integra lifesciences holding (IART) Related Businessweek News

No Related Businessweek News Found

integra lifesciences holding (IART) Details

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery; U.S. Extremities; U.S. Instruments; U.S. Spine and Other; and International. Its orthopedics products include specialty metal implants for surgery of the extremities, shoulder, and spine; orthobiologic products for repair and grafting of bone, including demineralized bone products, collagen ceramic matrices, and synthetic bone grafting solutions; dermal regeneration products and tissue-engineered wound dressings; and nerve and tendon repair products. The company also offers spinal fusion technologies comprising integrated interbody fusion devices, minimally invasive solutions, and deformity correction products; and neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. In addition, it provides extremity products, including bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist and shoulder arthroplasty, carpal tunnel syndrome, and cubital tunnel syndrome, as well as regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes. Further, the company offers instruments products, such as specialty and general surgical and dental instruments; and surgical lighting for hospitals, outpatient surgery centers, and physician, veterinarian, and dental practices. Integra LifeSciences Holdings Corporation sells its products directly through various sales forces and other distribution channels in the United States and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

3,400 Employees
Last Reported Date: 02/27/15
Founded in 1989

integra lifesciences holding (IART) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $827.8K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $537.3K
President of Specialty Surgical Solutions and...
Total Annual Compensation: $344.7K
Corporate Vice President, General Counsel, Ad...
Total Annual Compensation: $364.2K
Corporate Vice President of Global Operations...
Total Annual Compensation: $363.0K
Compensation as of Fiscal Year 2014.

integra lifesciences holding (IART) Key Developments

Integra LifeSciences Features New MAYFIELD(R) 2 System at the American Association of Neurological Surgeons Annual Scientific Meeting

Integra LifeSciences Holdings Corporation announced the introduction of the new MAYFIELD® 2 system for rigid cranial fixation. The MAYFIELD 2 system consists of a new Skull Clamp, along with a new Base Unit. The MAYFIELD 2 Skull Clamp is composed of a new stronger and lighter weight material. It includes an increased amount of off-set ratcheting teeth for more precise closure, an I-beam for smoother closure, and a new dual button release for easier removal. The MAYFIELD 2 Base Unit features a powder-coated finish, which allows automatic washing, and a swivel adaptor that does not require any additional tools for adjustment.

Integra LifeSciences Holdings Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Revises Earnings Guidance for the Full Year Ending December 31, 2015 and Provides Earnings Guidance for the Second Quarter of 2015; Reports Impairment Charges for the First Quarter Ended March 31, 2015

Integra LifeSciences Holdings Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's total revenues were $233,665,000 compared to $16,788,000 a year ago. Operating income was $16,788,000 compared to $8,738,000 a year ago. Income before income taxes was $12,617,000 compared to $3,975,000 a year ago. Net income was $8,384,000 or $0.25 per diluted share compared to $2,206,000 or $0.07 per diluted share a year ago. Adjusted EBITDA was $47,573,000 compared to $36,936,000 a year ago. Adjusted net income was $25,371,000 or $0.76 per diluted share compared to $18,610,000 or $0.57 per diluted share a year ago. Free cash flow was $22,718,000 compared to negative free cash flow of $81,000 a year ago. Net cash provided by operating activities was $31,619,000 compared to $11,254,000 a year ago. Purchases of property and equipment were $8,901,000 compared to $11,335,000 a year ago. For the second quarter of 2015, the company expects currency exchange rates to reduce revenue by about $8 million. The company expects second quarter revenue to be in the range of $240 million to $245 million, which assumes an organic growth rate of roughly 5%. The company expects second quarter adjusted EPS to increase slightly on a sequential basis over first quarter results. The company revised earnings guidance for the full year ending December 31, 2015. The revenue guidance is revised to $965 million to $980 million against previous guidance by $5 million. The company is also increasing its expectations for GAAP earnings per diluted share for the full year to be between $0.97 and $1.15, compared to prior guidance of $0.87 to $1.05. In addition, the company is raising it’s 2015 adjusted earnings per diluted share guidance to $3.15 to $3.33 from its prior range of $3.05 to $3.23. GAAP net income to be in the range of $32,391,000 to $38,591,000 and adjusted net income to be in the range of $105,400,000 to $111,600,000. For the full year of 2015, the company raised both GAAP and adjusted EPS guidance to $0.10. This equates to an adjusted EPS growth rate in the range of 6% to 13%, which excluding the effect of currency will be higher by approximately 5 to 7 points of growth. The company maintaining guidance for 2015 cash flow from operations to be in the range of $80 million to $90 million. The company continue to expect capital expenditures between $40 million and $45 million and a free cash flow conversion of 36% to 45%. This guidance includes the cost required for separating the Spine business, which expect to impact cash by approximately $20 million. It is increasing reported tax rate forecast to a range of 29% to 30% and adjusted tax rate to about 32%, because it expects a higher proportion of U.S.-based income for the remainder of the year. The company reported impairment charges of $409,000 for the first quarter ended March 31, 2015 against $600,000, last year.

Integra LifeSciences Holdings Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 09:20 AM

Integra LifeSciences Holdings Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 09:20 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Glenn G. Coleman, Chief Financial Officer, Principal Accounting Officer and Corporate Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IART:US $66.94 USD -1.15

IART Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chemed Corp $124.04 USD +0.14
Globus Medical Inc $25.74 USD -0.03
Masimo Corp $35.84 USD +0.32
NuVasive Inc $48.20 USD -0.03
Medicines Co/The $27.24 USD -0.24
View Industry Companies
 

Industry Analysis

IART

Industry Average

Valuation IART Industry Range
Price/Earnings 56.4x
Price/Sales 2.4x
Price/Book 3.3x
Price/Cash Flow 42.8x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTEGRA LIFESCIENCES HOLDING, please visit www.integralife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.